查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1677327

疫苗病毒服務市場按服務類型、技術、應用和最終用戶分類 - 2025 年至 2030 年全球預測

Vaccinia Virus Service Market by Service Type, Technology, Application, End Users - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

疫苗病毒服務市場在2024年的價值為12.8億美元，預計到2025年將達到13.5億美元，預計年複合成長率為5.94%，到2030年將達到18.1億美元。

主要市場統計數據
基準年 2024 年 12.8億美元
預計 2025 年 13.5億美元
預測年份 2030 18.1億美元
複合年成長率（%） 5.94％

全球醫療保健領域的發展促使行業相關人員採用革命性的技術和創新方法，特別是在疫苗接種和基於病毒的應用領域。經過多年的歷史使用和新興的研究興趣，痘苗病毒服務在分子醫學和治療發展方面取得了重大進展。本報告對痘苗病毒服務領域的現況、新興趨勢和策略機會進行了全面的分析。本報告深入探討了市場動態，超越傳統界限，評估了改變這一格局的科學、技術和臨床因素。

在基因編輯、病毒複製過程和診斷應用的堅實基礎的推動下，該領域有望加速成長。疫苗開發和臨床前研究對複雜解決方案的需求日益成長，迫使供應商開發技術先進、經過臨床檢驗的方法。本執行摘要是了解產業轉型、細分洞察以及不斷變化的區域和競爭動態的入口。

這裡提出的分析是基於嚴格的方法和全面的資料綜合。它不僅抓住了當前市場實踐的精髓，而且還指明了未來創新和策略市場滲透的途徑。透過根據多方面標準和區域影響力繪製詳細的細分圖，該研究強調了在不斷變化的高級病毒服務格局中保持競爭力的綜合方法的重要性。本介紹為更廣泛地討論這些動態因素如何影響基於痘苗病毒的應用的現在和未來奠定了基礎。

此外，本研究提供的深度分析整合了來自各個子領域的見解，為專家和決策者提供了快速發展領域的技術清晰度和營運有效性。透過這篇深入的說明，讀者將獲得關鍵趨勢和資料，為戰略決策提供資訊，確保在複雜、受監管和創新主導的環境中保持彈性並發揮競爭優勢。

改變疫苗和病毒服務市場

痘苗病毒服務領域最近的轉型轉變正在引入創造性創新，有可能重塑既定範式並重新定義市場運作。次世代定序和重組 DNA 技術的整合正在提高病毒檢測和表徵的準確性和有效性，從而更深入地了解病毒行為和治療潛力。

透過利用細胞培養技術的先進包裝以及病毒包裝和克隆方法的改進，服務供應商現在可以簡化病毒複製和擴增過程，同時提高可靠性和擴充性。這些技術突破對於臨床前和臨床試驗服務具有重要意義，因為嚴格的安全通訊協定和簡化的操作程序至關重要。

學術研究與實用化的融合，帶來了病毒載體工程的快速發展時代。基因編輯和基因工程開發能力的提高不僅加速了疫苗開發，而且有助於更廣泛地了解宿主-病原體相互作用。這正在引發整個診斷和治療領域的模式轉移。相關人員越來越需要適應多層次的法律規範和快速發展的科學需求，這迫使他們不斷重塑傳統方法。

隨著重組DNA技術的改進和病毒檢測範式的最佳化，創新的實驗模型正在成為主流。這些模型已成為完善市場策略和更準確預測結果的重要決策工具。因此，營運商正在重新考慮傳統的夥伴關係，並與技術供應商和學術機構建立策略聯盟，以降低風險並最大化成果。

以用戶為中心的服務設計模式的興起也推動了競爭格局的重塑，解決方案擴大根據製藥公司、政府機構和專業研究機構的獨特需求進行客製化。這種多樣化也體現在利用先進細胞培養方法和創新病毒載體工程的協同效應的整合系統的部署。摘要，市場正在經歷前所未有的變革，顛覆了長期存在的傳統觀念，並刺激了對研發的大量投資。

痘苗病毒服務市場的關鍵細分見解

痘苗病毒服務市場的細分分析為支持這個充滿活力的行業的各個方面提供了重要見解。按服務類型細分顯示，該市場得到了廣泛的研究，包括基因編輯和工程（處於設計新治療方法的前沿）以及臨床前和臨床試驗服務（確保新型疫苗候選物的安全性和有效性）。此外，病毒複製和擴增服務以及先進的病毒測試和表徵在確保產品品質和法規合規性方面發揮關鍵作用。業界對病毒生產服務的關注進一步凸顯了在受控環境中擴大生產規模所需的技術力。

深入挖掘，基於技術的細分同樣引人注目。細胞培養技術的應用仍然是該領域的基礎，為病毒繁殖和治療測試提供了基本平台。例如，次世代定序的創新透過提供詳細的基因組見解有助於推動個人化醫療的發展。與此相輔相成的是病毒包裝和克隆方法的進步，這些進步大大簡化了建構高效病毒載體的過程。此外，病毒載體工程的進步正在成為增強治療性介入介入的特異性和有效性的變革工具。

從應用角度來看，市場已從診斷、人類疫苗接種和研究等領域進行了分析。人類疫苗接種的進化軌跡以對猴痘和天花疫苗接種的專門研究為標誌，反映了對病毒感染疾病的防範以及與歷史病原體相關的風險因素的復甦的戰略重點。方面，研究應用，尤其是基因治療研究和廣泛的病毒學研究，對於闡明複雜的生物過程以及將實驗室的發現轉化為臨床實踐至關重要。如此多方面的細分不僅可以揭示明確的業務領域，還可以更深入地了解市場促進因素和障礙。

最後一個細分觀點是痘苗病毒服務的最終用戶。這個市場正在受到政府機構、製藥公司和研究機構的廣泛研究。特別是在製藥業，大企業和中小企業的差異凸顯了業務規模、投資能力和研究重點的差異，進而影響市場趨勢和創新週期。每個細分參數都強調了有針對性的策略的重要性，這些策略全面捕捉需求促進因素和特定客戶期望，並滿足服務、技術、應用和最終用戶維度上細微的市場需求。

總體而言，細分分析為理解推動痘苗病毒服務市場發展的多種因素提供了一個堅實的框架。這些競爭考察使相關人員能夠有效地協調業務和策略重點，使他們在面對技術變革和競爭挑戰時能夠靈活應對。

目錄

第 1 章 簡介

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 對客製化治療和改善患者治療效果的需求日益成長，推動了對標靶免疫療法治療的需求。
      • 大量政府資金和支持性法規結構正在刺激病毒載體技術的突破性研究並加速臨床試驗。
      • 全球意識的增強和對感染疾病預防的大量投入導致了痘苗病毒研究和開發活動的顯著增加。
    • 限制因素
      • 探勘、開發和生產擴張高成本，影響盈利
    • 機會
      • 病毒載體在基因治療、免疫治療和疫苗傳遞系統的應用不斷擴大
      • 生物製造流程和可擴展生產技術的持續進步將提高整體效率。
    • 任務
      • 不同司法管轄區的監管障礙和不斷變化的合規要求
  • 市場區隔分析
    • 服務類型：精準病毒載體改造的基因編輯與工程服務
    • 最終用戶：製藥業擴張增加疫苗病毒服務需求
  • 波特五力分析
  • PESTEL 分析
    • 政治的
    • 經濟
    • 社會的
    • 技術的
    • 合法的
    • 環境

6. 疫苗病毒服務市場依服務類型分類

  • 基因編輯和工程
  • 臨床前和臨床試驗服務
  • 病毒複製及擴增服務
  • 病毒檢測與鑑定
  • 病毒製造服務

7 疫苗病毒服務市場（依技術）

  • 細胞培養技術
  • 次世代定序
  • 重組DNA技術
  • 病毒包裝和克隆
  • 病毒載體工程

8. 疫苗病毒服務市場（依應用）

  • 診斷
  • 人類疫苗接種
    • 猴痘疫苗接種
    • 天花疫苗接種
  • 調查
    • 基因治療研究
    • 病毒研究

9. 疫苗病毒服務市場（依最終用戶分類）

  • 政府
  • 製藥公司
    • 大型企業
    • 中小型企業
  • 研究組織

10. 美洲疫苗病毒服務市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

11. 亞太疫苗與病毒服務市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

12. 歐洲、中東和非洲疫苗和病毒服務市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章 競爭格局

  • 2024 年市場佔有率分析
  • FPNV 定位矩陣，2024 年
  • 競爭情境分析
  • 戰略分析與建議

公司列表

  • ABL Biomanufacturing
  • Batavia Biosciences
  • Creative Biogene
  • Creative Biolabs
  • Emergent BioSolutions
  • Helvetica Health Care
  • KBI Biopharma
  • Leinco Technologies
  • Lonza Group AG
  • Matica Biotechnology Inc.
  • Merck KGaA
  • Microchem Laboratory
  • Oxford Biomedica AG
  • Sino Biological
  • Thermo Fisher Scientific
  • Vaccinex
  • Virology Research Services
  • Virovek
  • ZeptoMetrix
Product Code: MRR-B02FEF845E5C

The Vaccinia Virus Service Market was valued at USD 1.28 billion in 2024 and is projected to grow to USD 1.35 billion in 2025, with a CAGR of 5.94%, reaching USD 1.81 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.28 billion
Estimated Year [2025] USD 1.35 billion
Forecast Year [2030] USD 1.81 billion
CAGR (%) 5.94%

The evolution of the global healthcare sector has prompted industry stakeholders to embrace revolutionary technologies and innovative approaches, particularly in the realm of immunizations and virus-based applications. With longstanding historical use and renewed research interest, vaccinia virus services are making significant inroads into molecular medicine and therapeutic development. This report introduces a comprehensive analysis of the current state, emerging trends, and strategic opportunities within the vaccinia virus service sector. It provides an in-depth exploration of market dynamics, moving beyond traditional boundaries to assess the scientific, technological, and clinical factors that are reshaping the landscape.

Driven by a robust foundation of gene editing, viral replication processes, and diagnostic applications, the sector is poised for accelerated growth. Amid increasing demands for sophisticated solutions in vaccine development and preclinical research, providers are compelled to develop technologically advanced and clinically validated methods. In this context, the executive summary serves as the gateway to understanding transformative industry shifts, segmentation insights, and evolving regional and competitive dynamics.

The analysis presented herein is informed by rigorous methodologies and comprehensive data synthesis. It not only captures the essence of current market practices but also identifies future avenues for innovation and strategic market penetration. By mapping out detailed segmentation based on multifaceted criteria and regional influences, the research underscores the importance of an integrated approach to staying competitive in the ever-changing landscape of advanced virus services. This introduction sets the stage for an extended discussion on how these dynamic factors collectively shape both the present and the future of vaccinia virus-based applications.

Furthermore, the depth of analysis provided in the study integrates insights from various sub-domains, offering experts and decision-makers technical clarity and operational effectiveness in a rapidly evolving field. Through this detailed exposition, readers will gain access to critical trends and data that inform strategic decisions, thereby ensuring resilience and leveraging competitive advantages in a complex, regulated, and innovation-driven environment.

Transformative Shifts in the Vaccinia Virus Service Landscape

Recent transformative shifts in the vaccinia virus service landscape are reshaping established paradigms and introducing disruptive innovations that hold the potential to redefine market operations. The integration of next-generation sequencing and recombinant DNA technologies is enhancing the precision and efficacy of viral testing and characterization, thereby providing deeper insights into virus behavior and therapeutic potential.

Capitalizing on advances in cell culture technology and the refinement of viral packaging and cloning methodologies, service providers are now able to streamline viral replication and amplification processes with increased reliability and scalability. These technological breakthroughs have profound implications for both preclinical and clinical trial services, where rigorous safety protocols and streamlined operational procedures are paramount.

The convergence of academic research and practical application has led to an era where viral vector engineering is experiencing rapid evolution. Enhanced capabilities in gene editing and engineering not only accelerate vaccine development but also contribute to a broader understanding of host-pathogen interactions. This in turn is triggering a paradigm shift across diagnostic and therapeutic sectors. Stakeholders are increasingly confronted with the need to adapt to multi-layered regulatory frameworks and rapidly evolving scientific demands, which require constant reinvention of conventional methodologies.

Innovative experimental models are becoming mainstream, driven by enhanced recombinant DNA technologies and the optimization of viral testing frameworks. These models serve as crucial decision-making tools that help refine market strategies and forecast outcomes with greater precision. As a result, operators are rethinking traditional partnerships, forging strategic alliances with technology suppliers and academic institutions to mitigate risk and maximize successful outcomes.

The realignment in the competitive environment is also being fueled by the proliferation of user-centric design in service delivery, where solutions are increasingly tailored to meet the unique needs of pharmaceutical companies, government agencies, and dedicated research institutes. This diversification is also evident in the deployment of integrated systems that leverage the synergy between advanced cell culture methods and innovative viral vector engineering. In summary, the market is witnessing an unprecedented impetus for change, challenging long-held norms and stimulating substantial investment in research and development.

Key Segmentation Insights in the Vaccinia Virus Service Market

The segmentation analysis of the vaccinia virus service market offers critical insights into the various dimensions that underpin this dynamic field. Examining segmentation by service type reveals that the market is extensively studied across gene editing and engineering, which is at the forefront of novel therapeutic design, as well as preclinical and clinical trial services that ensure the safety and efficacy of new vaccine candidates. In addition, viral replication and amplification services, alongside advanced viral testing and characterization, play a pivotal role in ensuring product quality and regulatory compliance. The industry's focus on virus production services further underscores the technical prowess required to scale up manufacturing in a controlled environment.

Delving deeper, segmentation based on technology is equally compelling. The application of cell culture technology remains a cornerstone of the field, providing a fundamental platform for virus propagation and therapeutic testing. Innovations in next-generation sequencing, for instance, are now instrumental in advancing personalized medicine by offering detailed genomic insights, while recombinant DNA technology underpins numerous breakthroughs in viral vector design. Complementary to these is the evolution of viral packaging and cloning methods which have significantly streamlined the process of constructing high-efficiency viral vectors. Furthermore, advancements in viral vector engineering are emerging as transformative tools that enhance the specificity and potency of therapeutic interventions.

From an application standpoint, the market is analyzed across diagnostic, human vaccination, and research domains. The evolutionary trajectory of human vaccination has been marked by specialized studies in both monkeypox and smallpox vaccination, reflecting a strategic emphasis on preparedness against viral outbreaks and the resurgence of risk factors linked to historical pathogens. On another front, research applications - particularly in gene therapy research and broader viral research - are vital to decode complex biological processes and facilitate the translation of laboratory findings into clinical practice. Such multifaceted segmentation not only illuminates distinct operational domains but also enables a more granular understanding of market drivers and barriers.

The final segmentation perspective centers on the end users of vaccinia virus services. The market is extensively explored through the lens of government agencies, pharmaceutical companies, and research institutes. Notably, within the pharmaceutical domain, differentiation between large enterprises and small and medium enterprises highlights varying operational scales, investment capacities, and research priorities, which in turn affect market trends and innovation cycles. Each segmentation parameter offers a comprehensive view of demand drivers and client-specific expectations, reinforcing the importance of targeted strategies that cater to nuanced market needs across service, technology, application, and end user dimensions.

Overall, the segmentation analysis provides a robust framework to understand the diverse components that drive the vaccinia virus service market. These insights enable stakeholders to tailor their operational and strategic priorities effectively, ensuring that they remain agile in the face of technological shifts and competitive challenges.

Based on Service Type, market is studied across Gene Editing & Engineering, Preclinical & Clinical Trial Services, Viral Replication & Amplification Services, Viral Testing & Characterization, and Virus Production Services.

Based on Technology, market is studied across Cell Culture Technology, Next-Generation Sequencing, Recombinant DNA Technology, Viral Packaging & Cloning, and Viral Vector Engineering.

Based on Application, market is studied across Diagnostic, Human Vaccination, and Research. The Human Vaccination is further studied across Monkeypox Vaccination and Smallpox Vaccination. The Research is further studied across Gene Therapy Research and Viral Research.

Based on End Users, market is studied across Government Agencies, Pharmaceutical Companies, and Research Institutes. The Pharmaceutical Companies is further studied across Large Enterprises and Small & Medium Enterprises.

Regional Dynamics Shaping the Global Vaccinia Virus Market

Insightful regional analysis reveals a diverse tapestry of influences across key geographic areas, each contributing uniquely to the evolution of the vaccinia virus market worldwide. The Americas, for example, continue to be a critical hub for advanced medical research and technological innovation. This region benefits from a strong network of academic institutions, leading pharmaceutical companies, and robust governmental support, which all contribute to the rapid adoption and integration of advanced virus services into clinical practice.

In the Europe, Middle East & Africa region, regulatory rigor and public health initiatives underscore the strategic emphasis on vaccine innovation and safety. The presence of mature biotechnology sectors, combined with dynamic research ecosystems, positions this region as both a conservative yet forward-thinking market. Stakeholders here benefit from stringent quality control measures, which ensure that products meet high safety standards essential in vaccine production and therapeutic applications.

The Asia-Pacific region is emerging as a powerhouse of growth and innovation within the space. Rapid technological adoption, coupled with significant government investment in health infrastructure, has paved the way for dynamic expansion in both research and commercial production environments. This region is witnessing a surge in collaborative ventures and strategic partnerships that seek to leverage localized technological expertise with global best practices. These evolving dynamics not only underscore the potential for exponential growth but also highlight the need for adaptive strategies that can navigate regional regulatory complexities and market-specific challenges.

Collectively, these regional insights emphasize the importance of understanding local market drivers and regulatory contexts. By comparing technological adoption rates and investment climates across such diverse regions, service providers can better align their strategies to meet local demands while capitalizing on global trends. The interplay between regional expertise, rigorous regulatory oversight, and technological innovation is shaping a landscape that prioritizes both quality and scale in vaccinia virus production and application.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Company Contributions in Vaccinia Virus Services

A comprehensive review of the competitive landscape unveils the critical roles played by key industry players in driving overall market growth and innovation within the vaccinia virus services realm. Firms such as ABL Biomanufacturing, Batavia Biosciences, and Creative Biogene have been instrumental in pioneering cutting-edge methodologies and establishing best practices. These organizations work in tandem with leaders like Creative Biolabs and Emergent BioSolutions, who bring forward robust pipelines and comprehensive research expertise that strengthen the industry's advancement.

Further, influential companies including Helvetica Health Care, KBI Biopharma, and Leinco Technologies continue to provide unmatched quality and scalability in virus production operations. Their combined efforts in research and development serve as the backbone of technical and operational excellence. The participation of global giants such as Lonza Group AG, Matica Biotechnology Inc., and Merck KGaA highlights an unwavering commitment to innovation that drives the efficient translation of scientific breakthroughs into real-world therapeutic solutions.

Equally noteworthy are the contributions of Microchem Laboratory and Oxford Biomedica AG, whose technical acumen and robust research frameworks underscore the critical importance of quality control and precision engineering in this space. Sino Biological, Thermo Fisher Scientific, and Vaccinex further bolster this dynamic environment by offering state-of-the-art technologies that enable advanced diagnostic and clinical applications. Specialized firms like Virology Research Services, Virovek, and ZeptoMetrix continue to set high benchmarks in operational efficiency and technical precision.

The competitive interplay among these firms demonstrates a vibrant ecosystem where collaboration and innovation are central to driving forward the boundaries of vaccinia virus research and application. Their combined expertise provides a roadmap for best practices in quality assurance, technological adoption, and global market penetration, thereby directly influencing the pace at which therapeutic and diagnostic solutions evolve within the sector.

The report delves into recent significant developments in the Vaccinia Virus Service Market, highlighting leading vendors and their innovative profiles. These include ABL Biomanufacturing, Batavia Biosciences, Creative Biogene, Creative Biolabs, Emergent BioSolutions, Helvetica Health Care, KBI Biopharma, Leinco Technologies, Lonza Group AG, Matica Biotechnology Inc., Merck KGaA, Microchem Laboratory, Oxford Biomedica AG, Sino Biological, Thermo Fisher Scientific, Vaccinex, Virology Research Services, Virovek, and ZeptoMetrix. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to continuously invest in research and development initiatives while maintaining robust partnerships with technological innovators to stay ahead in the competitive vaccinia virus services market. Companies should prioritize leveraging integrated technological platforms, as these not only streamline processes but also enhance overall production efficiency. Embracing advanced cell culture systems, recombinant DNA technologies, and next-generation sequencing methods can drive improved accuracy in efficacy testing and quality control.

It is advisable for leaders to design strategic roadmaps that incorporate a deep understanding of both micro and macro market forces. This can be achieved by aligning product development initiatives with evolving regulatory standards and emerging scientific trends. Companies should maintain a focus on scalability in their operations, ensuring that innovations in viral replication, amplification, and vector engineering are seamlessly transitioned from the research bench to clinical and market settings.

Leaders are also urged to adopt a flexible and adaptive approach, one that leverages detailed segmentation insights to customize solutions for distinct market segments such as human vaccination, diagnostic applications, and specialized research contexts. Recognizing the variable needs of government agencies, pharmaceutical giants, and research institutes is crucial for crafting targeted strategies that maximize market penetration while mitigating potential risks associated with regulatory or technological disruptions.

Lastly, fostering strategic collaborations and investing in cutting-edge infrastructure will be essential for maintaining a competitive edge. By championing a culture of innovation and operational excellence, industry leaders can not only meet current market demands but also set the stage for unforeseen future advancements. Strategic foresight, combined with a commitment to continual innovation, will safeguard long-term growth and development in the rapidly evolving vaccinia virus service landscape.

Conclusion: Embracing the Future of Vaccinia Virus Services

In summary, the vaccinia virus service market stands at a pivotal juncture, defined by rapid technological evolution, diverse market segmentation, and expanding regional dynamics. The current landscape is characterized by a convergence of groundbreaking innovations in gene editing, cell culture technology, and viral vector engineering, each contributing to enhanced operational efficiencies and better clinical outcomes. This in-depth analysis underscores how robust segmentation strategies, coupled with focused regional insights, are enabling stakeholders to realize significant progress across various application domains.

The dynamic interplay between technological advancements and market demands underscores an era rife with opportunity and challenges. As the industry continues to evolve, it is imperative that key players and innovators harness the potential of advanced technologies in order to drive sustainable growth. The emphasis on quality, scalability, and regulatory compliance remains central to the sector's long-term success.

Stakeholders who remain agile, informed, and proactive will be well-equipped to navigate the complexities of this emerging landscape. A strategic approach that incorporates detailed segmentation, leverages regional strengths, and fosters cross-industry collaborations will be critical to securing a competitive advantage. The insights provided in this report serve as a strategic compass, guiding industry executives toward informed decision-making and robust market positioning in a field undergoing continuous transformation.

Looking forward, the future of vaccinia virus services is poised to benefit from sustained investments in research, innovative production techniques, and collaborative ecosystems. Through such concerted efforts, companies and research institutions will be better positioned to respond to both current needs and future challenges, ensuring that innovation remains the cornerstone of progress.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing demand for targeted immunotherapy treatment due to increasing need for customized therapies and improved patient outcomes
      • 5.1.1.2. Significant government funding and supportive regulatory frameworks fueling groundbreaking research and accelerating clinical trials in viral vector technology
      • 5.1.1.3. Rising global awareness and substantial investments in infectious disease prevention driving significant growth in vaccinia virus R&D activities
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research, development, and production scaling hamper profitability
    • 5.1.3. Opportunities
      • 5.1.3.1. Expanding applications of viral vectors across gene therapy, immunotherapy, and vaccine delivery systems
      • 5.1.3.2. Continuous advancements in bio-manufacturing processes and scalable production techniques improving overall efficiency
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles and evolving compliance requirements in various jurisdictions
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Service Type: Gene editing & engineering services tailored to achieve precise viral vector modifications
    • 5.2.2. End Users: Expansion of the pharmaceutical sector drives demand for vaccinia virus service
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Vaccinia Virus Service Market, by Service Type

  • 6.1. Introduction
  • 6.2. Gene Editing & Engineering
  • 6.3. Preclinical & Clinical Trial Services
  • 6.4. Viral Replication & Amplification Services
  • 6.5. Viral Testing & Characterization
  • 6.6. Virus Production Services

7. Vaccinia Virus Service Market, by Technology

  • 7.1. Introduction
  • 7.2. Cell Culture Technology
  • 7.3. Next-Generation Sequencing
  • 7.4. Recombinant DNA Technology
  • 7.5. Viral Packaging & Cloning
  • 7.6. Viral Vector Engineering

8. Vaccinia Virus Service Market, by Application

  • 8.1. Introduction
  • 8.2. Diagnostic
  • 8.3. Human Vaccination
    • 8.3.1. Monkeypox Vaccination
    • 8.3.2. Smallpox Vaccination
  • 8.4. Research
    • 8.4.1. Gene Therapy Research
    • 8.4.2. Viral Research

9. Vaccinia Virus Service Market, by End Users

  • 9.1. Introduction
  • 9.2. Government Agencies
  • 9.3. Pharmaceutical Companies
    • 9.3.1. Large Enterprises
    • 9.3.2. Small & Medium Enterprises
  • 9.4. Research Institutes

10. Americas Vaccinia Virus Service Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Vaccinia Virus Service Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Vaccinia Virus Service Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Matica Bio Partners with KaliVir
    • 13.3.2. Emergent biosolutions secures USD 400 million in contracts to boost vaccinia virus countermeasures and strengthen global biodefense preparedness
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ABL Biomanufacturing
  • 2. Batavia Biosciences
  • 3. Creative Biogene
  • 4. Creative Biolabs
  • 5. Emergent BioSolutions
  • 6. Helvetica Health Care
  • 7. KBI Biopharma
  • 8. Leinco Technologies
  • 9. Lonza Group AG
  • 10. Matica Biotechnology Inc.
  • 11. Merck KGaA
  • 12. Microchem Laboratory
  • 13. Oxford Biomedica AG
  • 14. Sino Biological
  • 15. Thermo Fisher Scientific
  • 16. Vaccinex
  • 17. Virology Research Services
  • 18. Virovek
  • 19. ZeptoMetrix

LIST OF FIGURES

  • FIGURE 1. VACCINIA VIRUS SERVICE MARKET MULTI-CURRENCY
  • FIGURE 2. VACCINIA VIRUS SERVICE MARKET MULTI-LANGUAGE
  • FIGURE 3. VACCINIA VIRUS SERVICE MARKET RESEARCH PROCESS
  • FIGURE 4. VACCINIA VIRUS SERVICE MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. VACCINIA VIRUS SERVICE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. VACCINIA VIRUS SERVICE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VACCINIA VIRUS SERVICE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. VACCINIA VIRUS SERVICE MARKET DYNAMICS
  • TABLE 7. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY GENE EDITING & ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY PRECLINICAL & CLINICAL TRIAL SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY VIRAL REPLICATION & AMPLIFICATION SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY VIRAL TESTING & CHARACTERIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY VIRUS PRODUCTION SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY CELL CULTURE TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY RECOMBINANT DNA TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY VIRAL PACKAGING & CLONING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY VIRAL VECTOR ENGINEERING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY MONKEYPOX VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY SMALLPOX VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY GENE THERAPY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY VIRAL RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY GOVERNMENT AGENCIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY LARGE ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY SMALL & MEDIUM ENTERPRISES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES VACCINIA VIRUS SERVICE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 137. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 144. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 151. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 158. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 165. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 180. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 187. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 194. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 201. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 208. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 215. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 222. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 229. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 236. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 243. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 250. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 257. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 264. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 271. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 278. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 285. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 292. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 299. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 306. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 313. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY HUMAN VACCINATION, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY RESEARCH, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM VACCINIA VIRUS SERVICE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
  • TABLE 327. VACCINIA VIRUS SERVICE MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 328. VACCINIA VIRUS SERVICE MARKET, FPNV POSITIONING MATRIX, 2024